# US 10,869,959 B2 · Method and device for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,959 B2
- Document ID: US10869959B2
- Status: Granted
- Kind: B2
- Application number: 15/600,384
- Filed: 2017-05-19
- Published: 2018-01-04
- Granted: 2020-12-22
- Earliest claimed: 2013-03-14
- Applicants: Brian J. Leberthon
- Inventors: Brian J. Leberthon
- Web page: https://patentgrep.com/patent/US10869959B2

## CPC

- A61M 1/3486: {Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents}
- A61M 1/3489: {by biological cells, e.g. bioreactor}
- A61M 1/3493: {using treatment agents in suspension}
- A61M 1/3616: {Batch-type treatment}
- A61M 1/362: {changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity}
- A61M 1/3687: {Chemical treatment (A61M1/3675 takes precedence)}
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions. Pore size is such to allow the molecular-sized activating agent in the interior of the chamber to enter the wells yet prevents immune cells and cancer cells in the wells to pass through the porous wall portions into the interior of the chamber. Blood is retained in the wells so that it remains in contact with the immune cells and cancer cells for a predetermined period sufficient to enhance an immune response. Then the cells with an enhanced immune response are return to the patient.

## Claims

### Claim 1

A method of treating cancer comprising the steps of
(a) positioning within an interior of a chamber an array of tubular passageways including porous membrane portions that enable a molecular-sized activating agent in a carrier fluid flowing through the chamber to pass through the porous membrane portions and enter a patient's blood flowing through the passageways,
said porous membrane portions configured to prevent immune cells and cancer cells in said blood flowing through the passageways to pass through said porous membrane portions into the interior of the chamber, and
(b) introducing the carrier fluid containing the molecular-sized activating agent into the interior of the chamber as the patient's blood flows through the passageways,
different activating agents being periodically introduced into the carrier fluid, one of the different activating agents being a chemotaxin and the other different activating agent being a cytokine, and
(c) retaining the patient's blood in the passageways to remain in contact with the immune cells and cancer cells in the patient's blood for a predetermined period sufficient to enhance an immune response.

### Claim 2 (depends on 1)

The method of claim 1 where the flow of blood through the passageways is countercurrent to the flow of carrier fluid through the interior of the chamber.